Aurenar closed an oversubscribed $5.7M seed round co-led by the American Heart Association's Go Red for Women Venture Fund and Solas BioVentures. The St. Louis company's V-Link platform delivers non-invasive vagus nerve stimulation through the outer ear to reduce cerebral vasospasm, a dangerous narrowing of blood vessels that follows a brain haemorrhage. A university trial reported a more than 40% reduction in moderate-to-severe vasospasm. The round follows the device's June FDA Breakthrough Device designation and funds development toward a pivotal trial.